muramylnac-ala-isogln-lys-tripeptide and Mouth Neoplasms

muramylnac-ala-isogln-lys-tripeptide has been researched along with Mouth Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dubielzig, RR; Everlith, K; Fidel, J; Fox, LE; Henry, C; Kurzman, ID; MacEwen, EG; Madewell, BR; Obradovich, J; Phillips, B; Rodriguez, CO; Rosenberg, M; Rosenthal, RC; Vail, DM; Zwahlen, CH	1

Trials

1 trial(s) available for muramylnac-ala-isogln-lys-tripeptide and Mouth Neoplasms

Article	Year
Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:12 Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Combined Modality Therapy; Cytotoxicity Tests, Immunologic; Dog Diseases; Dogs; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Liposomes; Male; Melanoma; Mouth Neoplasms; Survival Analysis	1999

Article

Year

Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:12

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Combined Modality Therapy; Cytotoxicity Tests, Immunologic; Dog Diseases; Dogs; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Liposomes; Male; Melanoma; Mouth Neoplasms; Survival Analysis

1999